Offshore Medical Billing and AI: Who Is Actually Touching Your Revenue Cycle?
More than half of all U.S. medical billing is now handled by third parties. A significant portion of that work is performed offshore, often without the physician or practice leader ever knowing. If your billing company is charging under 7 to 8 percent of collections depending on specialty, the question worth asking is not whether they are good at their job. The question is how they are making the economics work.
Hospital at Home After the 2030 Extension: Finance Leaders' 12-Month Planning Guide
The five-year waiver extension settled the existential planning question that had been stalling Hospital at Home investment for years. Finance leaders who deferred capital commitments pending Congressional action now have their answer: the Acute Hospital Care at Home program runs through September 30, 2030, and Florida health systems are moving.
Tampa General Hospital expanded its Hospital at Home program to Citrus County in March 2026, building on a flagship campus program at Davis Islands that has served more than 2,500 patients since 2022. Baptist Health Jacksonville operates a program treating pneumonia, COPD, cellulitis, and urinary tract infections. BayCare and Health First are among the broader Florida systems with federal approval to participate, alongside 138 systems and 365 hospitals across 37 states as of the most recent CMS data release.
The question is no longer whether Hospital at Home is a viable care model. The question is how finance leaders on both the provider and payer sides translate a five-year federal runway into 12-month operating decisions.
Healthcare Bankruptcy 2026: The CFO's Restructuring Playbook Before the 2027 Margin Cliff
Healthcare bankruptcy filings rose 33% in Q1 2026 compared to Q4 2025. That is not a warning sign on the horizon. It is a current condition playing out across physician practices, senior living facilities, and regional hospital systems right now. Gibbins Advisors tracked 12 major filings in Q1 alone, with liabilities exceeding $10 million each, and the pace is accelerating.
The organizations entering distress are not failing for lack of volume. They are failing because of capital structures built for a different interest rate environment, labor models that never fully adjusted after 2022, and payer mix assumptions that required commercial cross-subsidization to hold indefinitely. It hasn't.
For CFOs who are not yet in distress, the question is not whether the pressure is real. It is whether the restructuring work happens proactively, on your terms, or reactively, with an advisor already in the room.
Here is the four-part framework that separates the organizations navigating this moment from the ones sliding toward it.
340B Drug Pricing 2026: The CFO's 90-Day Action Plan and Long-Term Stability Framework
Eli Lilly sent hospitals a letter in late April warning of the "imminent loss" of 340B discounted pricing for any facility that failed to submit claims-level data without further delay. The American Hospital Association has pressed HRSA about this practice for months. As of late April 2026, HRSA has not publicly acted. Meanwhile, the agency is reconsidering a rebate model pilot that a federal court already vacated once, and CMS language in the most recent OPPS Final Rule hints at a payment reduction that could climb from 0.5 percent to 2 percent in future rulemaking. If your 340B program has not been reviewed in the past 90 days, the exposure is building faster than the policy process.
Healthcare Phishing Attacks Are Bypassing MFA: The CFO and CIO Operational Resilience Playbook
Microsoft Threat Intelligence issued a formal warning on May 4, 2026 that healthcare was the most targeted industry in a large-scale, multistage phishing campaign that reached more than 35,000 users across over 13,000 organizations, primarily in the United States. The attack used adversary-in-the-middle (AiTM) techniques to intercept authentication tokens in real time, enabling attackers to bypass multifactor authentication entirely and gain direct account access.
That last detail is the one that should command your full attention. MFA was supposed to be the floor. For healthcare organizations, it is no longer sufficient on its own.
No Margin, No Mission: What the Hospital Pricing Report Means for Health System CFOs
The Families USA report released May 7 landed exactly as these reports always do: with a headline that makes the morning news cycle and leaves finance leaders spending the next 48 hours fielding calls from board members. The finding that the 15 largest hospital systems charged an average of 282% of the Medicare rate, generating over $22 million in net income per hospital annually, framed the healthcare finance function as the problem.
The AHA responded the following day, calling the report "long on rhetoric and short on reality" and reiterating what anyone who has sat in a hospital CFO's chair already knows: hospitals are largely price takers, not price setters. Both statements contain real truth. Neither tells the full story your board actually needs.
Medicare GLP-1 Bridge 2026: The CFO Financial Planning Guide for Payer and Provider Leaders
CMS just announced that starting July 1, Medicare beneficiaries with Part D coverage can access GLP-1 medications for $50 per month through December 2027. The drug cost for health plans: zero. The operational and strategic exposure on both the payer and provider sides is not.
This is a demonstration program, not a permanent benefit. That distinction is exactly what makes the financial planning window so narrow.
The Latest Prior Authorization Reform: The CFO's Financial Planning Guide for CMS-0057-F
CMS published its roadmap for electronic prior authorization on May 5, 2026, and the headline is not that change is coming. The headline is that part of it already arrived. As of January 1, 2026, impacted payers across Medicare Advantage, Medicaid, CHIP, and Marketplace plans are legally required to return prior authorization decisions within 72 hours for urgent requests and 7 calendar days for standard requests. That is not a proposal. It is an operational mandate with public accountability attached.
For CFOs on both sides of the payer/provider divide, the 2026 PA reform cycle is not a single deadline. It is a phased infrastructure overhaul with financial consequences at each stage. Getting the sequence wrong will cost you more than the PA process itself.
Government and Academic Hospital Transfers: The CFO Due Diligence Framework When Public Assets Enter the Deal
A 3-2 city commission vote in Tallahassee was supposed to be the final political hurdle before a 772-bed hospital transferred from city ownership to Florida State University. Six weeks later, it became a lawsuit.
The Tallahassee Branch of the NAACP filed suit in late April alleging the city violated Florida statutory requirements governing the sale or transfer of public hospital property. The complaint specifically alleges the city failed to properly allocate sale proceeds for indigent care and economic development purposes, did not obtain Tallahassee Memorial HealthCare's consent, and did not offer the assets to TMH before approving the deal.
This isn't just a Tallahassee story. It is a framework problem that applies to every CFO evaluating a hospital transfer involving a government entity, academic partner, or publicly owned asset.
Health System Portfolio Rationalization: The CFO's Framework for Growing Up Instead of Out
The nation's largest nonprofit health systems are divesting hospitals at the same moment for-profit systems are reshaping their portfolios. CommonSpirit Health transferred Trinity Health System to UPMC, sold a critical access hospital in North Dakota, and is in the process of selling three more. Community Health Systems is divesting nine hospitals across four states for more than $1.2 billion. This is not a distress story. It is a strategy story.
The question every health system CFO needs to answer right now is not "where can we grow?" It is "where should we invest?" Those are different questions, and they carry very different capital implications.
Healthcare Process Automation: CFO Guide to FHIR, AI Workflows, and Operational Intelligence Beyond Revenue Cycle
A new Peterson Health Technology Institute (PHTI) report landed in April with a finding that should be uncomfortable for any finance leader who has been selling automation as a cost-reduction story. AI may actually be increasing healthcare costs by accelerating transaction volume without addressing underlying structural inefficiencies.
More prior authorization submissions. More billing activity. More back-and-forth between providers and payers. The technology works exactly as designed, and the result is more administrative spend, not less.
That is not an argument against automation. It is an argument for doing it correctly.
Provider-Sponsored Health Plans in 2026: The CFO's Financial Playbook for Making Payviders Work
Provider-sponsored Medicare Advantage enrollment dropped by nearly 60,000 members in 2025, while multiple health systems sold or shut down their plans entirely. At the same time, Kaiser Permanente added 58,000 MA members and UPMC's insurance division continues to fund system-wide expansion. The payvider model is not failing. But it is separating organizations that understood what they were getting into from those that did not.
Service Line Financial Assessment: The CFO's Framework for Capital Decisions That Actually Hold Up
When volume growth no longer guarantees margin growth, finance leaders need a sharper lens for service line investment decisions.
Hospital inpatient revenue grew 13% between 2021 and 2024. Outpatient revenue grew 31%. Operating margins fell 13% over that same period. If your service line investment strategy still rests on volume projections alone, you are making capital decisions with the wrong instrument.
Revenue Cycle Leadership Transitions: The Payer Restructuring Moment That Reframes Your First 90 Days
More than two dozen health systems have posted revenue cycle VP and director roles in the past two weeks. Boston Children's Hospital, RWJBarnabas Health, IU Health, Penn Medicine, Providence, and others are all actively recruiting. That volume of simultaneous openings does not happen because organizations suddenly got organized. It happens when finance and operational leadership have concluded that the current team is not positioned for what comes next.
When Healthcare AI Underperforms: A CFO Framework for Measuring, Documenting, and Making the Case for Better Tools
Payers are spending $1 billion to $1.5 billion on AI. Health systems are deploying it across revenue cycle, clinical decision support, and prior authorization workflows. And yet inside most finance departments right now, someone is quietly re-doing the work the AI was supposed to handle — catching errors, correcting output, and adding verification steps that weren't in the original workflow design.
That is the hidden cost nobody is measuring. And it belongs on your balance sheet.
Hospital Price Inflation vs. Insurer Margins: What the 2026 Cost Blame Game Means for Healthcare CFOs
A House Ways and Means Committee hearing this week produced something rare in Washington: bipartisan agreement. Lawmakers from both parties called hospital prices "borderline extortionary" and cited Bureau of Labor Statistics data showing hospital costs have risen 281% since 2000, roughly triple overall inflation. AHIP published supporting analysis the same week. The payer industry's case against provider pricing has never been better documented.
It is also strategically incomplete.
Medical Group Revenue Cycle: CFO and Director Strategies for the High-Deductible Patient Era
Twenty-nine percent of American adults now rank healthcare costs as the most urgent problem facing the U.S. healthcare system. That number matters to your revenue cycle because it signals exactly how your patients feel before they walk into your waiting room. When patients are already anxious about what they owe, every friction point in your billing process is a collections risk you cannot afford.
High-deductible health plans have fundamentally changed the revenue cycle math for medical groups. What used to be a straightforward payer relations problem has become a consumer finance problem. Your front desk is now a bank teller. Your billing department is a loan servicer. And your CFO is accountable for a self-pay accounts receivable balance that will keep growing unless your strategy evolves to meet it.
This is not a theoretical concern for future planning cycles. It is the operating reality of 2026.
Epic Is the EHR Market: A CFO's Guide to Contract Strategy When Leverage Is Limited
Epic's CEO Judy Faulkner recently told a podcast that profit is "a side effect, not a goal," and her company's $6.7 billion in 2025 revenue suggests the side effect is doing just fine. For every CFO sitting across a contract table from Epic, that philosophy has a financial translation: the rules are set, the market is consolidated, and the leverage most vendors leave on the table simply does not exist here. Understanding what that structure actually means for your organization is the first step toward protecting your margins.
IT Governance Is Now a Finance Problem for Health System CFOs
Your health system can now send, receive, and retrieve clinical data faster than at any point in the last decade. FHIR-based APIs are mainstream. TEFCA has moved from policy concept to live exchange infrastructure. And yet, your finance team is still running manual workarounds to pull clean data for the next board presentation.
The problem is not that data cannot move. The problem is that moving data and making data usable are two entirely different things. The gap between them is a finance leadership issue.
Value-Based Payment Models 2026: Health System CFO Strategy Guide for TEAM and CJR-X
The TEAM model launched in January 2026 across 740 hospitals, and six days before a major industry conference in April, CMS announced CJR-X, expanding mandatory bundles to every U.S. hospital for joint replacement starting in September 2027. If your organization is still treating value-based care as a future planning item, the window for reactive preparation is almost closed.